Foley Hoag LLP represented Ginkgo Bioworks on the agreement. Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Alcyone Therapeutics on the deal. Alcyone Therapeutics (Alcyone) announced the negotiation of a license and collaboration agreement with Biogen Inc. (Nasdaq: BIIB) to...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP advised HiFiBiO Therapeutics on the deal. FibroGen, Inc. (Nasdaq: FGEN) and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, Inc., the organism company, closed a collaboration and license agreement with Biogen (Nasdaq: BIIB) to...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, Inc., the organism company, closed a collaboration and license agreement with Biogen (Nasdaq: BIIB) to...
You must be a Standard 1 Year member to access this content.
